Leon Ullrich

Leon Ullrich

Auto-generated profile, based on publicly available information

Leon Ullrich

Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne, 50931, Germany

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2023 in Science Immunology
Verified
Journal Article
Closed access
TWTimm Weber
Timm Weber
SDSabrina Dähling
Sabrina Dähling
SRSvea Rose
Svea Rose
PAPatrick Affeldt
Patrick Affeldt
KVKanika Vanshylla
Kanika Vanshylla
FKFlorian Klein
Florian Klein
The human immune response must continuously adapt to newly emerging SARS-CoV-2 variants. To investigate how B cells respond to repeated SARS-CoV-2 antigen exposure by Wu01 booster vaccination and Omicron breakthrough infection, we performed a molecular longitudinal analysis of the memory B cell pool. We demonstrate that a subsequent breakthrough infection substantially increases the frequency of B cells encoding SARS-CoV-2–neutralizing antibodies. However, this is not primarily attributable to maturation, but to selection of preexisting B cell clones. Moreover, broadly reactive memory B cells arose early and even neutralized highly mutated variants like XBB.1.5 that the individuals had not encountered. Together, our data show that SARS-CoV-2 immunity is largely imprinted on Wu01 over the course of multiple antigen contacts but can respond to new variants through preexisting diversity.

9 December 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
LMLydia Meder
Lydia Meder
COCharlotte I. Orschel
Charlotte I. Orschel
CBCyrielle L. Bouchez
Cyrielle L. Bouchez
RGRahil Gholamipoorfard
Rahil Gholamipoorfard
COClaudia V. Orschel
Claudia V. Orschel
RURoland Tillmann Ullrich
Roland Tillmann Ullrich
Small cell lung cancer (SCLC) is characterized by its highly aggressive phenotype and dismal outcome. Despite the benefit of adding immune checkpoint blockade to standard chemotherapy, tumors acquire the ability to evade immunosurveillance and develop resistance. To investigate these underlying mechanisms, we perform high-dimensional profiling of human and murine SCLC specimens. In matched primary and metastatic human samples, we observe MHC-I loss in metastases, highlighting its role in immune evasion. Correspondingly, silencing MHC-I in SCLC cells drastically reduces immune infiltration and promotes metastasis in mice. Using mass spectrometry and phospho-tyrosine kinase analyses, we identify ERBB2 signaling as a suppressor of MHC-I and driver of immune-modulatory transcripts. Mechanistically, genetic and pharmacologic blockade of ERBB2 induces MHC-I in a STING-dependent manner and prevents immune evasion in autochthonous murine SCLC. Strikingly, combining ERBB2 inhibition with anti-PD-1 elicits profound synergistic responses in preclinical models, suggesting this combination for future clinical trials in SCLC patients.

24 January 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
KDKatharina Daniel
Katharina Daniel
LULeon Ullrich
Leon Ullrich
DRDenis Ruchnewitz
Denis Ruchnewitz
MMMatthijs Meijers
Matthijs Meijers
NHNico Joel Halwe
Nico Joel Halwe
FKFlorian Klein
Florian Klein
The repeated spill-over of Influenza A virus H5N1 clade 2.3.4.4b from cattle to humans highlights the risk of a human H5N1 pandemic. Given the impact of pre-existing immunity on the course and severity of viral infections, we assessed in detail the humoral immunity against the H5N1 A/Texas/37/2024 isolate in H5N1-naïve individuals. To this end, we performed complementary binding and neutralization assays on 66 subjects and ranked activities among a panel of 76 influenza A virus isolates. We detected low but distinct cross-neutralizing titers against A/Texas/37/2024 with a 3.9 to 15.6-fold reduction compared to selected H1N1 or H3N2 strains. Moreover, by cloning and evaluating 136 monoclonal antibodies from single memory B cells, we identified potent A/Texas/37/2024-neutralizing monoclonal antibodies in five out of six investigated individuals. These antibodies predominantly utilize VH1-69 gene segments, cross-neutralize H1, and compete with antibodies targeting the HA stem. Our findings demonstrate partial pre-existing humoral immunity to A/Texas/37/2024 in H5N1-naïve individuals.

17 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AAArtem Ashurov
Artem Ashurov
KHKatja Hoffmann
Katja Hoffmann
ARAjit R. Ramamohan
Ajit R. Ramamohan
KKKrithika P. Karthigeyan
Krithika P. Karthigeyan
AAAnna Ashurov
Anna Ashurov
MZMatthias Zehner
Matthias Zehner
SUMMARY: Humoral immune mechanisms that can contribute to limiting HCMV disease include neutralizing antibodies that block viral entry and Fc-mediated effector functions that promote elimination of infected cells. Here, we identify the gH/UL116 envelope complex as a naturally immunogenic target that elicits antibodies capable of mediating both of these immune mechanisms. Using single-cell sorting of antigen-specific memory B cells, we isolated gH/UL116-reactive monoclonal antibodies from HCMV-seropositive donors. Epitope mapping showed that gH binding was required for virus neutralization, whereas UL116 targeting was associated with potent and broad Fcγ receptor (FcγR) activation. Furthermore, cryo-electron microscopy provided high-resolution structures revealing how UL116-specific antibodies bind gH/UL116. In mice, gH/UL116 immunization elicited serum IgG responses whose binding titers strongly correlated with both neutralization and mouse FcγR activation. Together, these findings provide an epitope-level map linking antibody specificity to neutralization and FcγR activation across HCMV gH-associated complexes and position gH/UL116 as a promising HCMV vaccine candidate.